

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Ardana Bioscience Limited	03/25/2010
RECEIVING PARTY DATA	
Name:	Medical Research Council Technology
Street Address:	Lynton House, 7-12 Tavistock Square
Internal Address:	7th Floor
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	WC1H 9LT
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7098305
CORRESPONDENCE DATA	
Fax Number:	(212)294-4700
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2122946635
Email:	dkumar@winston.com
Correspondent Name:	WINSTON & STRAWN LLP - Allan A. Fanucci
Address Line 1:	1700 K Street N.W.
Address Line 2:	Patent Department
Address Line 4:	Washington, DISTRICT OF COLUMBIA 200063817
ATTORNEY DOCKET NUMBER:	87264-397
NAME OF SUBMITTER:	ALLAN A. FANUCCI
Total Attachments: 24 source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page1.tif source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page2.tif	

CH \$40.00 7098305

501361408

PATENT
REEL: 025424 FRAME: 0174

source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page3.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page4.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page5.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page6.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page7.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page8.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page9.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page10.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page11.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page12.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page13.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page14.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page15.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page16.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page17.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page18.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page19.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page20.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page21.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page22.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page23.tif
source=87264-397-Executed-Patent-Assignment-Appointment-Notice#page24.tif

07/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 3 / 9

Rule 2.23

Form 2.10B

Notice of Appointment of an Administrator by Company or Director(s)

(where a Notice of Intention to Appoint has not Been Issued)

Name of Company Ardana Bioscience Limited	Company number 04008598
In the High Court of Justice, Chancery Division [Full name of Court]	For court use only Court case number 5331108

(1) Insert name
and address of
registered office
of the company.

1. Notice is given that, in respect of ⁽¹⁾
Ardana Bioscience Limited, 5th Floor, Northwest Wing, Bush House,
Aldwych, London WC2B 4EZ

("the company")

(2) Delete as
appropriate.
(3) Give name(s)
and address(es) of
administrator(s).

⁽²⁾~~the company~~ [the directors of the company] ("the appointor") hereby appoints ⁽³⁾
David Kenneth Duggins of Ernst & Young LLP, One Coleman Square,
Birmingham B4 6HQ and Thomas Merchant Burton of Ernst & Young LLP 1 More
London Place, London SE1 2AF

as administrator(s) of the company.

2. The written statement(s) in Form 2.2B ⁽³⁾ ~~is/are~~ attached.3. The appointor is entitled to make an appointment under paragraph 22 of
Schedule B1 to the Insolvency Act 1986.

4. This appointment is in accordance with Schedule B1 to the Insolvency Act 1986.

5. The company has not, within the last twelve months:-

- (i) been in administration
- (ii) been the subject of a moratorium under Schedule A1 to the Insolvency Act 1986
which has ended on a date when no voluntary arrangement was in force
- (iii) been the subject of a voluntary arrangement which was made during a
moratorium for the company under Schedule A1 to the Insolvency Act 1986 and
which ended prematurely within the meaning of section 7B of the Insolvency Act
1986.

6. In relation to the company there is no:

- (i) petition for winding up which has been presented but not yet disposed of
- (ii) administration application which has not yet been disposed of, or
- (iii) administrative receiver in office.

7. The company ⁽³⁾ ~~is not~~ ⁽¹⁾ [an insurance undertaking] [a credit institution] [an
investment undertaking providing services involving the holding of funds or
securities for third parties] or [a collective investment undertaking under Article 1.2
of the EC Regulation].



C:\Documents and Settings\clintonson\Local Settings\Temporary Internet Files\OLK28A\PRACTICE\5331108\1-Form_2

(P.T.O.)
INV_108/1

Duration: 05.07.2010 16:45:34 - 05.07.2010 16:46:35. This page 3 of 9 was completed at 05.07.2010 16:45:55

Received at the EPO on Jul 05, 2010 16:46:35. Page 3 of 9

07/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 4 / 9

(4) Insert whether
main or territorial
proceedings.

8. For the following reasons it is considered that the EC Regulation: ⁽²⁾ (will) (will not) apply. If it does apply, these proceedings will be ⁽⁺⁾ main proceedings as defined in Article 3 of the EC Regulation:
The Company's registered office and administration of the Company's interests is conducted within England and Wales

9. Attached to this notice is ⁽²⁾ ~~a copy of the resolution of the company to appoint an administrator~~ [a record of the decision of the directors to appoint an administrator].

10. Where there are joint administrators, a statement for the purposes of paragraph 100(2) of Schedule B1 to the Insolvency Act 1986 is attached.
⁽³⁾ ⁽⁴⁾ John Graham Lee, 38 Melville Street, Edinburgh, EH3 7HA
a director of the Company

(5) Insert name and
address of person
making declaration.
(6) If making the
declaration on behalf
of appointor indicate
capacity e.g.
director/solicitor.

here do solemnly and sincerely declare that:

- (i) the company is or is likely to become unable to pay its debts
- (ii) the company is not in liquidation, and
- (iii) the statements in paragraphs 5 and 8 are, so far as I am able to ascertain, true,

and that the information provided in this notice is to the best of my knowledge and belief true,

AND I make this solemn declaration conscientiously believing the same to be true and by virtue of the Statutory Declarations Act 1835.

Declared at Edinburgh.

Signed [Signature]

this 30th day of June 2008

before me Mandy Delevy, MANDY DELEVY

A Commissioner for Oaths or Notary Public or Justice of the Peace or Solicitor or
Duly Authorised Officer

(7) Insert date and
time.

Endorsement to be completed by the Court
This notice was filed ⁽⁷⁾ 14.54 30/6/8



OYOZ 7 Spa Road, London SE16 3JN
© Crown copyright

Insolvency - Company 2.108

C:\Documents and Settings\lhamson\Local Settings\Temporary Internet

9.2008

INS_108/2

Duration: 05.07.2010 16:45:34 - 05.07.2010 16:46:35. This page 4 of 9 was completed at 05.07.2010 16:46:04

Received at the EPO on Jul 05, 2010 16:46:35. Page 4 of 9

07/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 5 / 9

Rule 2.3

Form 2.2B

Statement of proposed administrator

Name of Company Ardana Bioscience Limited	Company number 04008598
In the High Court of Justice, Chancery Division <small>[full name of court]</small>	<i>For court use only</i> Court case number

(a) Insert name and address of proposed administrator

1.
(a) I David Kenneth Duggins of Ernst & Young LLP, One Colmore Square, Birmingham B4 6HQ

hereby certify that I am authorised under the provisions of Part XIII of the Insolvency Act 1986 to act as an insolvency practitioner.

I.P. No.: 8324Name of Regulatory Body: ICAEW

(b) Insert name of company

2. I consent to act as administrator of (b) Ardana Bioscience Limited

* Delete as applicable

("the company") in accordance with the Application / notice of appointment of

(c) Insert name of person presenting administration application or making the appointment

(c) directors of the Company

(d) Insert date of application or appointment

dated (d) 30th June 2008

* Delete as applicable

3. I am of the opinion that the purpose of administration is reasonably likely to be achieved.

4. I ~~have~~ / have not had any prior professional relationship with the company.

(I attach to this Statement a short summary of any prior professional relationship(s) with the company.)

Signed

Dated

[Signature]30th June 2008

17/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 6 / 9

Rule 2.3

Form 2.2B

Statement of proposed administrator

Name of Company Ardana Bioscience Limited	Company number 04008598
In the High Court of Justice, Chancery Division (full name of court)	For court use only Court case number

(a) Insert name and address of proposed administrator
 1. 1
 (a) Thomas Merchant Burton of Ernst & Young LLP | More London Place, London SE1 2AF

hereby certify that I am authorised under the provisions of Part XIII of the Insolvency Act 1986 to act as an insolvency practitioner.

I.P. No.: 8824

Name of Regulatory Body:

INSTITUTE OF CHARTERED ACCOUNTANTS OF SCOTLAND

(b) Insert name of company
 2. I consent to act as administrator of (b) Ardana Bioscience Limited

* Delete as applicable

("the company") in accordance with the ~~Application~~ notice of appointment of

(c) Insert name of person presenting administration application or making the appointment
 (c) directors of the company

(d) Insert date of application or appointment

dated (d) 30 JUNE 2008

* Delete as applicable

3. I am of the opinion that the purpose of administration is reasonably likely to be achieved.

4. I ~~have~~ have not had any prior professional relationship with the company.

(I attach to this Statement a short summary of any prior professional relationship(s) with the company.)

Signed [Signature]

Dated 30 JUNE 2008

nodma\pdocs\practice\8297536\1 slm

Duration: 05:07:2010 16:46:34 - 05:07:2010 16:46:35. This page 6 of 9 was completed at 05:07:2010 16:46:16

Received at the EPO on Jul 05, 2010 16:46:35. Page 6 of 9

PATENT

REEL: 025424 FRAME: 0179

07/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 7 / 9


RESOLUTION BY COMPANY RE APPOINTMENT OF ADMINISTRATOR(S)

EXTRACT from the MINUTES of Telephonic
MEETING of the DIRECTORS of ARDANA
BIOSCIENCE LIMITED (the "Company") held
on Sunday 29 June 2008 at 4.55pm

It was resolved, that having regard to the financial position of the Company, it would be in the best interests of the Company and its creditors for the Company to enter administration. It was noted that David Kenneth Duggins of Ernst & Young LLP, One Colmore Square, Birmingham B4 6HQ and Thomas Merchant Burton of Ernst & Young LLP 1 More London Place, London SE1 2AF were duly qualified to act as Administrators and it was resolved that arrangements should be made for them to be appointed as Administrators of the Company.

Certified as a true Extract.

Signed by Secretary



ardana/patent/proc/025424/2010/07/05/03:45:02 PM

Duration: 05.07.2010 16:45:34 - 05.07.2010 16:46:35. This page 7 of 9 was completed at 05.07.2010 16:46:21

Received at the EPO on Jul 05, 2010 16:46:35, Page 7 of 9

17/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 8 / 9

STATEMENT PURSUANT TO PARAGRAPH 100(2) OF
SCHEDULE B1 TO THE INSOLVENCY ACT 1986

NAME OF COMPANY: Ardara Bioscience Limited
COMPANY NUMBER: 04008598

It is intended that

FULL NAME: David Kenneth Duggins

ADDRESS: Ernst & Young LLP, One Colmore Square, Birmingham B4 6HQ

FULL NAME: Thomas Merchant Burton

ADDRESS: Ernst & Young LLP 1 More London Place, London SE1 2AF

are to be appointed as Joint Administrators of the above Company.

Pursuant to paragraph 100(2) of Schedule B1 to the Insolvency Act 1986 it is specified that:

- (a) the functions to be exercised by the joint administrators are all functions which the joint administrators will require to exercise in relation to their appointment; and
- (b) the functions which require to be exercised by the joint administrators in relation to their appointment will be exercised by whichever joint administrator is more available and better qualified to exercise such function, and in certain cases by both.

Signed by



Partner

For and on behalf of Dundas & Wilson LLP

Northwest Wing, Bush House

Aldwych, London, WC2B 4EZ

As Solicitor and Agent for and on behalf of the Company

\\ndm\pc\cc\cc\practical\029743211.sln

Duration: 05:07:2010 16:45:34 - 05:07:2010 16:46:35. This page 8 of 9 was completed at 05:07:2010 16:46:28

Received at the EPO on Jul 05, 2010 16:46:35. Page 8 of 9


PATENT

REEL: 025424 FRAME: 0181

17/05/2010 03:45:02 PM

Potter Clarkson LLP ->

Page 9 / 9



Payment of fees and expenses

European Patent Office
Treasury and Accounts
60296 München
Germany
Fax +49 (0) 89 2399-4465

Please complete in typscript only

01	Name of payer Potter Clarkson LLP	Payee reference MEDCD/P27518EP
	Address Park View House 68 The Ropewalk Nottingham, England	Mode of payment <input type="checkbox"/> Bank payment/transfer to <input checked="" type="checkbox"/> Not a pre deposit account with the EPO is requested
02	Patent application/patent No. (please use a separate form for each application)	Deposit account No. 28050040
03	EP 10003046.9	PCT

	Code	Description	Currency	Amount
04	001	Filing fee - EP direct*	EUR	
05	002	Search fee	EUR	
06	005	Designation fee(s)*	EUR	
07	015	Claims fee(s) (Rules 45(1), 192(1) EPC)*	EUR	
08	055	Additional copy	EUR	
09	005	Examination fee	EUR	
10	007	Fee for grant*	EUR	
11	008	Additional fee for printing specification (more than 35 pages)*	EUR	
12	003	Renewal fee for the 3rd year	EUR	
13	004	Renewal fee for the 4th year	EUR	
14	005	Renewal fee for the 5th year	EUR	
15	020	Filing fee - entry EP phase*	EUR	
16		Extension fee(s) for**	EUR	
17	022	Register Transfer Fee	EUR	90.00
18	022	Register Transfer Fee - Additional	EUR	90.00
19			EUR	
20			EUR	
21			EUR	
22		Total	EUR	180.00

EPO 8010 04/05

Signature *Anders*

Name 1-8 not official

NOTTM 17 June 10
Place, date

Duration: 05.07.2010 16:46:34 - 05.07.2010 16:46:35. This page 9 of 9 was computed at 05.07.2010 16:46:35

Received at the EPO on Jul 05, 2010 16:46:35. Page 9 of 9

PATENT ASSIGNMENT

between

ARDANA BIOSCIENCE LIMITED (IN ADMINISTRATION)

and

THE ADMINISTRATORS

and

MEDICAL RESEARCH COUNCIL TECHNOLOGY

DUNDAS & WILSON CS LLP

Northwest Wing
Bush House
Aldwych
London
WC2B 4EZ

Tel: 020 7240 2401
Fax: 020 7240 2448
DX: DX127LDE

Ref: CH/JB/ERN004.0066

INDEX

CLAUSE	PAGE
1. Definitions and Interpretation	2
2. Assignment	3
3. Transfer of Product Data	4
4. Limitation of Liability	5
5. Exclusion of Representations and Warranties	6
6. Confidentiality	6
7. General	6
 SCHEDULES	
Schedule 1 Patent Applications	8
Schedule 2 Product Data	13

THIS AGREEMENT is made on the 25th day of March 2010

BETWEEN

ARDANA BIOSCIENCE LIMITED (IN ADMINISTRATION) whose registered office is at 5th Floor, North West Wing, Bush House, Aldwych, London WC2B 4PA (registered number 4008598) (Ardana) acting by its Joint Administrators David Duggins and Tom Burton of Ernst & Young LLP (the Administrators) appointed by virtue of a notice of appointment dated 30 June 2008;

THE ADMINISTRATORS (in their capacity as Joint Administrators of Ardana); and

MEDICAL RESEARCH COUNCIL TECHNOLOGY a private company limited by guarantee whose registered office is at 7th Floor, Lynton House, 7-12 Tavistock Square, London, WC1H 9LT (registered number 2698321) (MRCT),

(each a "party" and together the "parties").

WHEREAS

- A. Ardana is the owner of certain patents and patent applications as listed in Schedule 1 and of certain Product Data as listed in Schedule 2, all relating to the Product.
- B. MRCT wishes to acquire, and Ardana has agreed to transfer to MRCT, the Patent Rights and Product Data on the terms and conditions set out in this Agreement.

NOW IT IS HEREBY AGREED AS FOLLOWS:

1. DEFINITIONS AND INTERPRETATION

- 1.1 In this Agreement unless the context otherwise requires:

Dundas and Wilson means the Administrators' solicitors, Dundas and Wilson CS LLP, whose place of business is at 191 West George Street, Glasgow, G2 2LD;

Effective Date means the date of this Agreement;

Patent Rights means (i) the patents and patent applications listed in Schedule 1, (ii) all and any patent applications which claim priority from the patents and/or patent

applications listed in Schedule 1, (iii) all and any patents granted pursuant to the patents and/or patent applications referred to in (i) and (ii) above, and (iv) all and any reissues, extensions, substitutions, continuations, divisions, continuations-in-part, supplementary protection certificates and other extensions of term relating to the patent applications and patents referred to in (i), (ii) and (iii) above;

Product means the product known as "Teverelix", the gonadotrophin releasing hormone antagonist developed by Ardana; and

Product Data means the following clinical, pre-clinical, scientific and technical data (relating to the Product) which are currently in Ardana's control and possession: (i) the electronic data contained in the data room hosted by Dundas and Wilson to which MRCT has been given access prior to the Effective Date; and (ii) the hard copy documentation that is currently held in storage by Ardana, all as set out in Schedule 2.

- 1.2 References in this Agreement to the singular include the plural and vice versa.
- 1.3 References in this Agreement to Clauses and Schedules are to clauses of and schedules to this Agreement.
- 1.4 Headings to Clauses and Schedules are inserted for convenience only and shall not affect the construction or interpretation of this Agreement.
- 1.5 This Agreement may be executed on any number of counterparts by the different parties or separate counterparts, each of which when executed and delivered shall constitute an original but all of which shall together constitute one and the same instrument.

2. ASSIGNMENT

- 2.1 In consideration of the sum of one pound sterling (£1) (receipt of which Ardana hereby acknowledges), Ardana hereby assigns and transfers to MRCT (but only to the extent that Ardana has such rights and is able to assign them to MRCT), and MRCT hereby accepts the assignment of:

- 2.1.1 whatever right, title and interest Ardana has in and to the Patent Rights and the full and exclusive benefit of them and all rights, privileges and advantages associated with them throughout the world, including, but not limited to, the right to apply for patents in all countries which may be designated in any of the patent applications which are PCT applications;

- 2.1.2 the right to claim priority from the Patent Rights under the Paris Convention (as amended) and under any other relevant International Convention or Treaty for each country or territory constituted by the relevant Convention or Treaty in which application may be made;
 - 2.1.3 the benefit of all existing priority dates in relation to the Patent Rights; and
 - 2.1.4 such rights as Ardana may have to sue for and obtain injunctive relief, damages and other relief in respect of any infringement or misuse of the Patents Rights, any of the rights conferred by the publication of the Patent Rights or any of the other rights referred to in this Clause 2.1, whether such infringements take place before or after the Effective Date; and
 - 2.1.5 whatever right, title and interest Ardana has in and to the Product Data.
- 2.2 Ardana hereby undertakes at the request and cost of MRCT (such request to be made within during the period that Ardana is in Administration otherwise the obligations of Ardana contained in this Clause 2.2 shall unconditionally lapse and be of no further force and effect), to the extent that Ardana has the power to do so, to do all things and execute or procure the execution of all such further documents, forms and authorisations as may be reasonably required to vest Ardana's full property, rights, title and interest in and to the Patent Rights in MRCT absolutely, including but not limited to registration of MRCT's title as proprietor at relevant patent offices anywhere in the world and to assist in the resolution of any question concerning the Patent Rights.
- 2.3 Ardana shall promptly following the Effective Date instruct its patent agents, Potter Clarkson, that all records and correspondence which Potter Clarkson holds relating to the Patent Rights are to be held to the order of MRCT from the Effective Date.
- 2.4 Immediately from the Effective Date, any fees, costs, expenses, damages, claims and losses whatsoever that become due and/or payable in respect of the Patent Rights will be due and payable by MRCT.

3. TRANSFER OF PRODUCT DATA

- 3.1 On the Effective Date, Ardana shall make the Product Data available for collection by MRCT from Dundas and Wilson's Glasgow office. MRCT shall collect the Product Data from Dundas and Wilson within two (2) weeks following the Effective Date between the days of Monday and Friday during the hours of 9am to 5.30pm (local time).

- 3.2 MRCT acknowledges that the Product is experimental in nature. Ardana neither warrants nor guarantees that the Product Data are fit for any particular purpose, of satisfactory quality and/or free from encumbrances or other third party rights or claims and/or that no payments will require to be paid to third parties in order to gain access to or make use of the Product Data.

4. LIMITATION OF LIABILITY

- 4.1 It is an essential condition of this Agreement:

4.1.1 that the Administrators contract solely as agents of Ardana and shall incur no personal liability of whatsoever nature (whether directly or indirectly, express or implied) and howsoever arising including without prejudice to the foregoing generality, personal liability in respect of any action or actions of whatsoever nature and howsoever arising in pursuance of Ardana's rights and/or obligations under this Agreement and whether such claim is formulated in contract and/or tort or by reference to any other remedy or right, and in whatever jurisdiction or forum;

4.1.2 that no claim which may be or become competent to MRCT arising directly or indirectly from this Agreement (or under any deed or other document executed in consequence hereof or on or under any associated or collateral agreement or arrangement) will lie against the Administrators personally and the Administrators shall be entitled at any time to have any such deeds, documents or others amended to include an exclusion of personal liability in terms of this Clause 4; and

4.1.3 that any personal liability of the Administrators which would in terms of the Insolvency Act 1986 arise but for the provisions of this Clause 4 is hereby expressly excluded.

- 4.2 The Administrators have joined in as parties to this Agreement solely for the purpose of obtaining the benefit of the provisions of this Clause 4 and any other provisions in this Agreement in their favour.

- 4.3 Nothing in this Agreement shall constitute a waiver of any right of the Administrators to be indemnified, or to exercise a lien, whether under the provisions of the Insolvency Act 1986 or otherwise howsoever.

- 4.4 For the purpose of this Clause 4, references to "the Administrators" where the context so permits shall mean and include their present and future firm or firms,

partners and employees, and any legal entity or partnership using in its name the words "Ernst & Young LLP", and the partners, shareholders, officers and employees of any such entity or partnership.

5. EXCLUSION OF REPRESENTATIONS AND WARRANTIES

- 5.1 MRCT agrees that in entering into this Agreement it is not relying upon any information, warranty, statement, representation, silence or non provision of information on the part of the Administrators or any of their solicitors, employees, agents, representatives, or anyone acting for them or on their behalf or all or any of them, whether or not made within any document prepared by or on behalf of the Administrators (whether acting as agents of Ardana or otherwise) and that MRCT is not relying upon any other written or oral representation made to it or to its representatives or agents by the Administrators or their representatives or agents.
- 5.2 All representations, warranties and conditions, express or implied, statutory or otherwise (including, without limitation, warranties and representations as to right, title or interest) in respect of the Patent Rights or Product Data or any part thereof are hereby expressly excluded.
- 5.3 Nothing in this Agreement is to require Ardana and/or the Administrators to discharge in whole or in part any liability of Ardana outstanding at the time of the Administrators' appointment.

6. CONFIDENTIALITY

- 6.1 The terms and conditions of this Agreement shall be maintained confidential by the parties and neither party shall issue a press release or other announcement regarding the Agreement. Notwithstanding the foregoing, MRCT acknowledges that Ardana and the Administrators shall be entitled to disclose such terms of the Agreement as are necessary to any creditors, creditors committees and/or any court of competent jurisdiction or otherwise as may be required by operation of law.

7. GENERAL

- 7.1 This Agreement shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the Courts of England and Wales.

- 7.2 If any term or provision or any part thereof contained herein shall be declared or become unenforceable, invalid or illegal in any respect under the law of any relevant jurisdiction, such term or provision or part thereof shall be deemed to have been severed from the remaining terms of this Agreement and the terms and conditions hereof shall remain in full force and effect as if this Agreement had been executed without the offending provision appearing herein and the parties shall endeavour to agree an amendment which to the fullest extent possible will give lawful effect to their intentions as expressed in any term or provision severed.
- 7.3 The parties enter into the terms of this Agreement on behalf of themselves and all successors and assigns. Subject thereto, a person who is not a party to this Agreement has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement but this does not affect any right or remedy of a third party which exists or is available apart from that Act.

SCHEDULE 1
PATENT APPLICATIONS

(i) *Teverelix per se - Luteinizing hormone releasing hormone antagonist peptides*

Country	Filing date (priority)	Application No (Publication No)	Status	Expiry Date (projected)
CA (Potter Clarkson ref ARDCD/P27520CA)	17.03.92 ⁽¹⁾ (25.04.91)	2108977 (2108977)	Granted	17.03.12
EP ⁽²⁾ (Potter Clarkson ref ARDCD/P27520EP)	17.03.92 ⁽¹⁾ (25.04.91)	92906562.1 (0693491)	Granted	17.03.12
HK (Potter Clarkson ref ARDCD/P27520HK)	17.03.92 ⁽¹⁾ (25.04.91)	98105279.4 (1006172)	Granted	17.03.12
JP (Potter Clarkson ref ARDCD/P27520JP)	17.03.92 ⁽¹⁾ (25.04.91)	505977/92 (2719233)	Granted	17.03.12
KR (Potter Clarkson ref ARDCD/P27520KR)	17.03.92 ⁽¹⁾ (25.04.91)	93/703206 (0210472)	Granted	17.03.12
US (Potter Clarkson ref ARDCD/P27520US)	17.03.92 ⁽¹⁾ (25.04.91)	08/140,045 (5,516,887)	Granted	17.03.12

Notes:

- (1) These patent applications derive from an international patent application (PCT/EP92/00572; WO 1992/19651) with this filing date.

- (2) The granted European Patent has been nationally validated in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, Spain, Sweden, Switzerland, The Netherlands, UK and Monaco.

Applicant: Ardana Bioscience Limited

Inventors: R Deghenghi

Priority: US Application No. 0690861, filed 25 April 1991.

(ii) *Teverelix LA - Sustained release of microcrystalline peptide suspensions*

Country	Filing date (priority)	Application No (Publication No)	Status	Expiry Date (projected)
AR <i>(Potter Clarkson ref ARDCD/P27518AR)</i>	05.09.02 (06.09.01)	P020103358	Pending	05.09.22
AU <i>(Potter Clarkson ref ARDCD/P27518AU)</i>	27.08.02 ⁽¹⁾ (06.09.01)	2002337025 (2002337025)	Granted	27.08.22
BR <i>(Potter Clarkson ref ARDCD/P27518BR)</i>	27.08.02 ⁽¹⁾ (06.09.01)	PI0212333-9	Pending	27.08.22
BY <i>(Potter Clarkson ref ARDCD/P27518BY)</i>	27.08.02 ⁽¹⁾ (06.09.01)	a20040308	Pending	27.08.22
CA <i>(Potter Clarkson ref ARDCD/P27518CA)</i>	27.08.02 ⁽¹⁾ (06.09.01)	2459309	Pending	27.08.22
CN <i>(Potter Clarkson ref ARDCD/P27518CN)</i>	27.08.02 ⁽¹⁾ (06.09.01)	02817377.5 (ZL02817377.5)	Granted	27.08.22

EP: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR (Potter Clarkson ref ARDCD/P27518EP)	27.08.02 ⁽¹⁾ (06.09.01)	02772214.9 (1423150)	Pending	27.08.22
HK (Potter Clarkson ref ARDCD/P27518HK)	27.08.02 ⁽¹⁾ (06.09.01)	04105185.0	Pending	27.08.22
HU (Potter Clarkson ref ARDCD/P27518HU)	27.08.02 ⁽¹⁾ (06.09.01)	P0402099-	Pending	27.08.22
IL (Potter Clarkson ref ARDCD/P27518IL)	27.08.02 ⁽¹⁾ (06.09.01)	160443	Pending	27.08.22
IN (Potter Clarkson ref ARDCD/P27518IN)	27.08.02 ⁽¹⁾ (06.09.01)	00271/KOLNP/200 4 (234007)	Granted	27.08.22
IN (divisional) (Potter Clarkson ref: ARDCD/P27518INdiv 1)	27.08.02 ⁽¹⁾ (06.09.01)	5005/KOLNP/2007	Pending	27.08.22
JP (Potter Clarkson ref ARDCD/P27518JP)	27.08.02 ⁽¹⁾ (06.09.01)	2003-526373	Pending	27.08.22
KR (Potter Clarkson ref ARDCD/P27518KR)	27.08.02 ⁽¹⁾ (06.09.01)	10-2004-7003371 (818904)	Granted	27.08.22

KR (divisional) <i>(Potter Clarkson ref ARDCD/P27518KRdi v1)</i>	27.08.02 ⁽¹⁾ (06.09.01)	10-2007-7021972	Abandoned	-
MX <i>(Potter Clarkson ref ARDCD/P27518MX)</i>	27.08.02 ⁽¹⁾ (06.09.01)	PA/a/2004/002185	Pending	27.08.22
NO <i>(Potter Clarkson ref ARDCD/P27518NO)</i>	27.08.02 ⁽¹⁾ (06.09.01)	20040938	Pending	27.08.22
NZ <i>(Potter Clarkson ref ARDCD/P27518NZ)</i>	27.08.02 ⁽¹⁾ (06.09.01)	531734 (531734)	Granted	27.08.22
PL <i>(Potter Clarkson ref ARDCD/P27518PL)</i>	27.08.02 ⁽¹⁾ (06.09.01)	P-368066	Pending	27.08.22
RU <i>(Potter Clarkson ref ARDCD/P27518RU)</i>	27.08.02 ⁽¹⁾ (06.09.01)	2004110615 (2311195)	Granted	27.08.22
SG <i>(Potter Clarkson ref ARDCD/P27518SG)</i>	27.08.02 ⁽¹⁾ (06.09.01)	200401238-1 (102988)	Granted	27.08.22
TW <i>(Potter Clarkson ref ARDCD/P27518TW)</i>	29.08.02 (06.09.01)	91119713 (1249409)	Granted	29.08.22
UA <i>(Potter Clarkson ref ARDCD/P27518UA)</i>	27.08.02 ⁽¹⁾ (06.09.01)	2004031905 (79435)	Granted	27.08.22

US <i>(Potter Clarkson ref ARDCD/P27518US)</i>	19.02.02 (06.09.01)	10/080,130 (7,098,305)	Granted	09.04.23 ⁽²⁾
US (continuation 1) <i>(Potter Clarkson ref ARDCD/P27518USc on1)</i>	19.02.02 ⁽³⁾ (06.09.01)	11/450,292	Pending	19.02.22
US (continuation 2) <i>(Potter Clarkson ref ARDCD/P27518USc on2)</i>	19.02.02 ⁽³⁾ (06.09.01)	11/450,293	Pending	19.02.22
ZA <i>(Potter Clarkson ref ARDCD/P27518ZA)</i>	27.08.02 ⁽¹⁾ (06.09.01)	2004/1390 (2004/1390)	Granted	27.08.22

Notes:

- (1) These patent applications derive from an international patent application (PCT/EP02/09537; WO 2003/022243) with this filing date.
- (2) Includes a patent term extension of 414 days.
- (3) These patent applications are continuations of a US patent application (US 10/080,130) with this filing date.

Applicant: Ardana Bioscience Limited

Inventors: F Boutignon and R Deghenghi

Priority: US Application No. 60/317616, filed 6 September 2001.

**SCHEDULE 2
PRODUCT DATA**

- Whatever clinical, pre-clinical, scientific and technical information documentation that are contained in the thirty-two (32) boxes of hard copy documentation (relating to the Product) currently held in storage by Ardana and with the following box numbers:
 - 570274224;
 - 570274225;
 - 570274226;
 - 570274227;
 - 570274228;
 - 570274229;
 - 570274230;
 - 570274231;
 - 570274232;
 - 570274233;
 - 570274234;
 - 570274235;
 - 570274236;
 - 570274237;
 - 570274238;
 - 570274239;
 - 570274240;
 - 570274241;
 - 570274242;

- 570274243;
 - 570274244;
 - 570274245;
 - 570274246;
 - 570274247;
 - 570274248;
 - 570274249;
 - 570274250;
 - 570274251;
 - 570274252;
 - 570274253;
 - 570274254; and
 - 570274264.
- A DVD consisting of electronic copies of the clinical, pre-clinical, scientific and technical information documentation (relating to the Product) which are contained in the data room hosted by Dundas and Wilson and to which MRCT has been given access prior to the Effective Date.

In witness whereof the parties have caused this Agreement to be signed as a deed and delivered on the date first written above.

Signed as a Deed by

Ardana Bioscience Limited (in
Administration) by

David Kenneth Diggins



one of the Administrators (without
incurring personal liability on the part
of either of the Administrators) in the
presence of this witness:

Neaou

Witness

Martina Pugh

Full Name

C/O CMS + Young
1 more London Place
London
SE1 2AF

Address

Signed as a Deed by

The Administrators by

David Kenneth Diggins



one of the Administrators (without
incurring personal liability on the part
of either of the Administrators) in the
presence of this witness:

Neaou

Witness

Martina Pugh

Full Name

C/O CMS + Young
1 more London Place
London
SE1 2AF

Address

Signed as a Deed by
Medical Research Council Technology
by

Carol Coshra-Moore

Authorised Signatory

P. Ronald Byrne.....Witness

PETER RONALD BYRNE Full Name

1-3 BURTONHOLE LANE Address

MILL HILL, LONDON

NW7 1AD